Effects of Different Urodynamic Characteristics on Therapeutic Outcomes of Overactive Bladder Medication in a Real-life Clinical Practice

Overview

Journal Tzu Chi Med J

Specialty General Medicine

Date 2022 Dec 29

PMID 36578645

Authors

Hsiu-Jen Wang

Hann-Chorng Kuo

Affiliations

Soon will be listed here.

Abstract

Objective: This study retrospectively investigated the influence of urodynamic parameters and patient characteristics on success rates among patients with overactive bladder (OAB) and urodynamic detrusor overactivity (DO).

Materials And Methods: Consecutive patients with OAB and urodynamic DO initially received solifenacin, mirabegron, or combination of both for 1-3 months. If failed, patients were switched to another OAB medication subtype or provided additional OAB medication for a total of 6 months. A successful treatment was defined as an improvement in urgency severity and a global response assessment of ≥1. Success rates after initial or modulated OAB medication were analyzed based on patient and urodynamic characteristics.

Results: A total of 453 patients were enrolled, among whom 144, 255, and 54 received solifenacin, mirabegron, and combined medications, respectively. Among the patients, 259 (57.2%) had OAB dry and 194 (42.8%) had OAB wet. Patients receiving mirabegron alone had a significantly higher initial medication success rate compared to that of others. Patients with a phasic DO (50.7%), bladder outlet obstruction (BOO, 52.5%), and no central nervous system (CNS) lesions (47.5%) exhibited higher success rates than those with a terminal DO (42.0%), no BOO (42.7%), and CNS lesions (31.6%), respectively. After switching or modulating the initial OAB medication following treatment failure, 115 (62.2%) of 185 patients still showed improvement in OAB symptoms, with an overall success rate of 70.2% after 6 months of treatment.

Conclusion: Initial solifenacin or mirabegron treatment had a success rate of around 50%. In general, patients with a phasic DO, urodynamic BOO, and no CNS lesions have higher success rates than those with a terminal DO, no BOO, and CNS lesions, respectively. Success rates can further be improved by switching or modulating OAB medication.

Citing Articles

Declining utilization of urodynamic studies in urological care in Germany: time to say goodbye?.

Baunacke M, Kontschak L, Menzel V, Grabbert M, Borkowetz A, Mehralivand S World J Urol. 2024; 42(1):440.

PMID: 39046605 PMC: 11269447. DOI: 10.1007/s00345-024-05154-3.

Urinary beta 3-adrenoceptor as a diagnostic biomarker for overactive bladder in women.

Liang C, Hsieh W, Lo T, Huang T, Chou Y, Huang J Sci Rep. 2023; 13(1):19368.

PMID: 37938600 PMC: 10632490. DOI: 10.1038/s41598-023-46786-6.

Urinary Oxidative Stress Biomarker Levels Might Be Useful in Identifying Functional Bladder Disorders in Women with Frequency and Urgency Syndrome.

Jiang Y, Jhang J, Kuo H J Clin Med. 2023; 12(6).

PMID: 36983336 PMC: 10057901. DOI: 10.3390/jcm12062336.

References

Chung S, Liao C, Chen Y, Kuo H . Urgency severity scale could predict urodynamic detrusor overactivity in patients with overactive bladder syndrome. Neurourol Urodyn. 2011; 30(7):1300-4. DOI: 10.1002/nau.21057. View

Chapple C . Muscarinic receptor antagonists in the treatment of overactive bladder. Urology. 2000; 55(5A Suppl):33-46; discussion 50. DOI: 10.1016/s0090-4295(99)00492-6. View

Kuo H . Videourodynamic analysis of pathophysiology of men with both storage and voiding lower urinary tract symptoms. Urology. 2007; 70(2):272-6. DOI: 10.1016/j.urology.2007.03.063. View

Moorthy P, Lapitan M, Quek P, Lim P . Prevalence of overactive bladder in Asian men: an epidemiological survey. BJU Int. 2004; 93(4):528-31. DOI: 10.1111/j.1464-410x.2003.04682.x. View

McVary K, Roehrborn C, Avins A, Barry M, Bruskewitz R, Donnell R . Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011; 185(5):1793-803. DOI: 10.1016/j.juro.2011.01.074. View

Sebastianelli A, Russo G, Kaplan S, McVary K, Moncada I, Gravas S . Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine. Int J Urol. 2017; 25(3):196-205. DOI: 10.1111/iju.13498. View

Liao C, Kuo H . High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment. Medicine (Baltimore). 2016; 95(45):e4962. PMC: 5106046. DOI: 10.1097/MD.0000000000004962. View

Kay G, Abou-Donia M, Messer Jr W, Murphy D, Tsao J, Ouslander J . Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2006; 53(12):2195-201. DOI: 10.1111/j.1532-5415.2005.00537.x. View

Nitti V, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo J . Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013; 67(7):619-32. PMC: 3752932. DOI: 10.1111/ijcp.12194. View

10.

Abrams P, Kelleher C, Staskin D, Kay R, Martan A, Mincik I . Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II.... World J Urol. 2016; 35(5):827-838. DOI: 10.1007/s00345-016-1908-1. View

11.

Gormley E, Lightner D, Faraday M, Vasavada S . Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015; 193(5):1572-80. DOI: 10.1016/j.juro.2015.01.087. View

12.

Wang C, Jiang Y, Kuo H . Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder. Low Urin Tract Symptoms. 2017; 9(1):27-32. DOI: 10.1111/luts.12103. View

13.

Sexton C, Notte S, Maroulis C, Dmochowski R, Cardozo L, Subramanian D . Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract. 2011; 65(5):567-85. DOI: 10.1111/j.1742-1241.2010.02626.x. View

14.

Milsom I, Abrams P, Cardozo L, Roberts R, Thuroff J, Wein A . How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001; 87(9):760-6. DOI: 10.1046/j.1464-410x.2001.02228.x. View

15.

Nitti V, Rosenberg S, Mitcheson D, He W, Fakhoury A, Martin N . Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013; 190(4):1320-7. DOI: 10.1016/j.juro.2013.05.062. View

16.

Igawa Y, Michel M . Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. Naunyn Schmiedebergs Arch Pharmacol. 2012; 386(3):177-83. DOI: 10.1007/s00210-012-0824-1. View

17.

Chiu A, Liao C, Wang C, Wang J, Tsai C, Kuo H . High classification of chronic heart failure increases risk of overactive bladder syndrome and lower urinary tract symptoms. Urology. 2011; 79(2):260-5. DOI: 10.1016/j.urology.2011.10.020. View

18.

Lee Y, Kuo H . Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities. Geriatr Gerontol Int. 2018; 18(9):1330-1333. DOI: 10.1111/ggi.13465. View

19.

Stewart W, Van Rooyen J, Cundiff G, Abrams P, Herzog A, Corey R . Prevalence and burden of overactive bladder in the United States. World J Urol. 2003; 20(6):327-36. DOI: 10.1007/s00345-002-0301-4. View

20.

Benner J, Nichol M, Rovner E, Jumadilova Z, Alvir J, Hussein M . Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2009; 105(9):1276-82. DOI: 10.1111/j.1464-410X.2009.09036.x. View